According to the announcement, the CLSA PREMIUM (06877) announced its mid-term business performance in 2024, with a total operating business income of HKD 55.501 million, a 60.89% decrease year-on-year; a net profit of HKD 6.26 million, a 12.71% increase year-on-year; and an earnings per share of 0.31 HK cents.

The announcement stated that the decrease in net profit was mainly due to a decrease in revenue and an increased focus on high gross margin B2C businesses by the group, thereby increasing the gross margin of the health business.